The Record
Every lock. Every score. Every country.
Each forecast is committed to a public criterion before the outcome is known and scored against that exact criterion afterwards. Misses are published in full. Pick a country on the Atlas, a month, a status, or search the calls.
Showing 3 of 360 ·Hit ×Denmark ×Next 90 days ×Clear all
November 20262 locks resolved
| Ref | The locked call | Resolves | Status |
|---|---|---|---|
| P-186 | Vestas FY2026 margin floorVestas keeps FY2026 EBIT margin floor ≥7% at Q3 (raised from 6-8%) — ~0.88HIT — locked Vestas keeping its FY2026 EBIT margin before special items guidance floor at or above 7%. Its Q3 interim report on 11 Nov 2026 narrowed the range to 7.5-8.5% (previously 7-9%); the floor rose to 7.5%. The top end fell, which is why headlines read it as a cut; the lock was on the floor.Denmark | 11 Nov 2026locked 13 Aug 2026 | Hit |
| P-164 | Maersk Q3 2026 underlying EBITDAMaersk Q3 2026 underlying EBITDA ≥US$2.2bn (~27% below Q2) — ~0.92HIT — locked Maersk Q3 2026 underlying EBITDA of at least US$2.2bn. Maersk's Q3 interim report (5 Nov 2026) shows underlying EBITDA of US$4,718m, more than double the floor, and full-year guidance was raised. Freight rates were the most volatile input this series locks, which is why the floor was wide; it was not in contention.Denmark | 5 Nov 2026locked 13 Aug 2026 | Hit |
August 20261 lock resolved
| Ref | The locked call | Resolves | Status |
|---|---|---|---|
| P-92 | Novo Nordisk Wegovy Q2 2026Novo Wegovy franchise sales grow Q2 > Q1 2026 — ~0.80HIT - Wegovy franchise grew Q2>Q1: Wegovy pill DKK 2,256M -> 3,141M (+885M QoQ); Novo beat on Wegovy and raised FY guidance, obesity-care sales up. Pill-driven; the injectable faced YoY price pressure.Denmark | 5 Aug 2026locked 24 Jun 2026 | Hit |